8thANNUAL DRUG DISCOVERY FOR NEURODEGENERATION CONFERENCE:

An Intensive Course on Translating Research into Drugs


Presented by the Alzheimer's Drug Discovery Foundation

February 2-4, 2014  ●  Miami, FL 

PROGRAM

Sunday, February 2, 2014
2:00 pm – 4:00 Registration
4:00 – 4:20 Welcome & Opening Remarks: Challenges and Opportunities in Academic Drug Discovery
Howard Fillit, MD
— Alzheimer's Drug Discovery Foundation  
4:20 – 5:05 Plenary – Functional Approaches to CNS Drug Discovery and the Potential for Drugs with Multiple Targets as a Mechanism of Action
Frank Sams-Dodd, PhD, DSc
— Willingsford Ltd  
5:05 – 5:15 Q&A
5:15 – 5:20 Closing Remarks
Howard Fillit, MD
— Alzheimer's Drug Discovery Foundation
5:20 – 7:00 Welcoming Reception
Monday, February 3, 2014
8:00 am – 8:30 Continental Breakfast
8:30 – 8:35 Welcome & Opening Remarks
Lorenzo Refolo, PhD
— National Institute on Aging
8:35 – 8:50 Preclinical Therapeutics Development for Neurological Disorders: Funding & Resources
Patricia Ann Walicke, MD, PhD
— National Institute of Neurological Disorders and Stroke 
I. Introduction to Small Molecule Chemistry for Biologists
Chair: D. Martin Watterson, PhD — Northwestern University
8:50 – 9:25 Overview: Themes in Successful Prior Art for Novel Small Molecule Discovery in CNS Disorders
D. Martin Watterson, PhD
— Northwestern University 
9:25 – 9:35 Q&A
9:35 – 10:10 Synthetic Chemistry Fundamentals in Lead Compound Refinement
Jeff Pelletier, PhD
— Fox Chase Chemical Diversity Center, Inc.
10:10 – 10:20 Q&A
10:20 – 10:40 Natural Products as Drug Starting Points
Frank Koehn, PhD
— Pfizer Inc.
10:40 – 10:50 Q&A
10:50 – 11:20 Break
II. Embarking on a Drug Discovery Campaign
Chair: Kalpana Merchant, PhD — Eli Lilly and Company
11:20 – 11:25 Session Overview – Kalpana Merchant, PhD, Eli Lilly and Company
11:25 – 11:45 De-risking Parkinson's Disease Drug Development via Optimal Target Validation and Decision-driving Biomarkers
Kalpana Merchant, PhD
— Eli Lilly and Company
11:45 – 11:55 Q&A
11:55 – 12:15 Using Chemical Probes for Target Validation and to Understand Target Liability
Jian Jin, PhD
— University of North Carolina at Chapen Hill 
12:15 – 12:25 Q&A
12:25 – 12:45 Assembling the Right Interdisciplinary Team From the Beginning
Julie Frearson, PhD
— Biofocus
12:45 – 12:55 Q&A
12:55 – 1:55 Lunch and Poster Session BREAKOUT I. Emerging Trends and Practical Aspects of Medicinal Chemistry Refinement
III. Drug Discovery: From Screening to Clinical Candidate
Chair: Edward Spack, PhD—Fast Forward, LLC
1:55 – 2:00 Session Overview – Edward G. Spack, PhD, Fast Forward, LLC
2:00 – 2:20 New Trends in High Throughput Screening (HTS): Rapid and Inexpensive Discovery of Natural Product-like Molecules for Probe and Drug Development
Thomas Kodadek, PhD
— Scripps Florida
2:20 – 2:30 Q&A
2:30 – 2:50 Compound Optimization after HTS: From Hit to Lead
Kurt Brunden, PhD
— University of Pennsylvania
2:50 – 3:00 Q&A
3:00 – 3:20 Designing a Therapeutic Animal Study: Employing Translatable Biomarkers
Manfred Windisch, PhD
NeuroScios - Neuroscience Optimized Solutions
3:20 – 3:30 Q&A
3:30– 3:50 Break
3:50– 4:10 Requirements for an IND and Early Considerations
Edward Spack, PhD
— Fast Forward, LLC
4:10 – 4:20 Q&A
4:20 – 4:40 When Should You Engage a Contract Research Organization?
Katya Tsaioun, PhD
— Pharma Launcher
4:40 – 4:50 Q&A
4:50 - 5:10 ADDF ACCESS Program and Closing Remarks
Rachel Lane, PhD
— Alzheimer's Drug Discovery Foundation
5:10 – 5:30 Break: Networking Tips Session - University of Miami Toppel Career Center
5:30 – 6:30 Networking Reception and Poster Session
Tuesday, February 4, 2014
8:00 am – 8:30 Continental Breakfast
8:30 – 8:35 Welcome & Opening Remarks
Diana Shineman, PhD
— Alzheimer's Drug Discovery Foundation
8:35 – 9:05 Plenary – The Story of Lyrica: Academic Discovery to Commercial Success
Rick Silverman, PhD
— Northwestern University 
9:05 – 9:15 Q&A
IV. Strategies for Challenging CNS Targets – Case Study Examples
Chair: Marcie Glicksman, PhD—Harvard NeuroDiscovery Center
9:15 - 9:20 Session Overview - Marcie Glicksman, PhD — Harvard NeuroDiscovery Center
9:20 – 9:40 Case Study: From Bench to High Throughput Screen
Marcie Glicksman, PhD
— Harvard NeuroDiscovery Center
9:40 – 9:50 Q&A
9:50 – 10:10 Innate Immune Modulatory Strategies for ALS and Alzheimer's Disease 
Todd Golde, MD, PhD
— University of Florida
10:10 – 10:20 Q&A
10:20 – 10:40 Development of Small Molecule Hepatocyte Growth Factor Mimetic for the Treatment of Dementia 
Joseph Harding, PhD
— M3 Biotechnology
10:40 – 10:50 Q&A
10:50 – 11:10 Break
11:10 – 11:30 Allopregnanolone: From Laboratory Discovery to Clinical Trial
Roberta Diaz Brinton, PhD
— University of Southern California
11:30 – 11:40 Q&A
11:40 – 12:00 BACE Inhibition for Alzheimer's Disease: Validation of Target Engagement
Mark Forman, MD, PhD
— Merck & Co., Inc.
12:00 – 12:10 Q&A
12:10 – 1:10 pm Lunch and Poster Session BREAKOUT II. Discussion on Lessons Learned with Case Study Speakers
V. Developing Science into Products
Chair: Kurt Brunden, PhD — University of Pennsylvania
1:10 – 1:15 Session Overview - Kurt R. Brunden, PhD — University of Pennsylvania
1:15 – 1:35

Novel Approaches to Technology Transfer: Pharma-Academia Collaborations

Robert Zivin, PhD - University of Miami

1:35 – 1:45 Q&A
1:45 – 2:05 Innovation in Tech Transfer and the Role of the Tech Transfer Office
Todd Huffman, PhD
— The Scripps Research Institute
2:05 – 2:15 Q&A
2:15 – 2:35 A Re-Understanding of How to Protect and use Intellectual Property
Leslie Meyer-Leon, PhD, JD
— IP Legal Strategies Group PC
2:35 – 2:45 Q&A
2:45 – 3:05 Break
VI. What do Partners Looks For? A Perspective from Pharma, Private Investors and Philanthropy
Chair: Frank Longo, MD, PhD — Stanford University and PharmatrophiX
3:05 -3:15 Introduction: Challenges in Securing Partnerships
Frank Longo, MD, PhD
— Stanford University & PharmatrophiX 
3:15 – 3:55 Panel Discussion: What do Partners Look For?

Adrian Howd, PhD — Evotec AG

Sanjeev Munshi, PhD — Merck & Co., Inc.

Dennis Yamashita, PhD — GlaxoSmithKline

Marco Baptista, PhD — Michael J. Fox Foundation for Parkinson's Research

3:55 – 4:10pm Q&A
4:10 – 4:15pm Closing Remarks - Howard Fillit, MD, Alzheimer's Drug Discovery Foundation